US Patent

US10610502 — Oral baclofen solutions

Method of Use · Assigned to Metacel Pharmaceuticals LLC · Expires 2039-08-30 · 13y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects aqueous oral solutions of the drug baclofen, including formulations with and without a buffer, and an assay for detecting an impurity in baclofen solutions.

USPTO Abstract

The present disclosure relates to aqueous oral solutions comprising baclofen. In one embodiment, the aqueous oral solutions comprise a buffer comprising citric acid, a salt of citric acid, or any combination thereof, and are stored at from about 2° C. to about 8° C. The present disclosure also relates to buffer free aqueous oral solutions comprising baclofen. Additionally, the present disclosure relates to an assay for determining the amount of an impurity, 4-(3-carboxymethyl)-3-hydroxy-2,5-dioxopyrrolidin-1-yl)-3-(4-chlorophenyl)butanoic acid, in a baclofen containing solution, and to methods of treatment using such aqueous oral solutions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2779 — Lioresal

Patent Metadata

Patent number
US10610502
Jurisdiction
US
Classification
Method of Use
Expires
2039-08-30
Drug substance claim
No
Drug product claim
No
Assignee
Metacel Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.